ATO combined with idarubicin regimen synergistically enhances antileukemic effects.[11] ATO combined with gemtuzumab ozogamicin (GO) targets CD33 to eradicate minimal residual disease, particularly in individuals with high tumor burden or high CD33 expression.[12,13] For patients harboring FLT3/ITD mutations, the addition of FLT3 inhibitors,such as sorafenib can significantly improve therapeutic outcomes.[14] The patient had experienced multiple relapses and had failed to achieve complete remission after several lines of chemotherapy. This evidence concerns the gene CD33 and neoplasm.